Highlights:
Creation of a pure play pharmaceuticals business
Eurovetsuccessfully integrated and expected synergies realised
Divestment of the Services Segment completed on 16 August 2013, generating proceeds of £87.5 million. Net cash position after receipt of the proceeds is circa £7.0 million
Underlying diluted EPS for continuing operations at 29.07 pence, growth of 42.2% versus last year (at constant exchange rate)
Profit before tax on continuing operations up by 59.7% (at constant exchange rate) benefiting from a full year of Eurovet and a solid core performance
Group revenue on continuing operations up by 56.6% (at constant exchange rate) despite slow trading in the third quarter and third party supply issues in the US
Focus therapeutic areas in companion animal products grew by 11.2% (at constant exchange rate)
Increased investment in Research and Development to support the product pipeline and enlarged Group post-Eurovet acquisition
Dividend per share up 14.1% to 14.00 pence
